Skip to main content

Table 1 Oncologist characteristics in the physician survey and medical records review studies

From: Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

  Physician survey Medical records review
Characteristic Rounds 1 & 2
(N = 301)
Round 3
(N = 152)
Total
(N = 453)
Rounds 1 & 2
(N = 79)
Round 3
(N = 40)
Total
(N = 119)
Country, n (%)
 France 89 (29.6) 39 (25.7) 128 (28.3) 23 (29.1) 11 (27.5) 34 (28.6)
 Germany 79 (26.2) 43 (28.3) 122 (26.9) 26 (32.9) 11 (27.5) 37 (31.1)
 Italy 46 (15.3) 29 (19.1) 75 (16.6) 6 (7.6) 4 (10.0) 10 (8.4)
 Spain 44 (14.6) 22 (14.5) 66 (14.6) 8 (10.1) 4 (10.0) 12 (10.1)
 Czech Republic 18 (6.0) 6 (3.9) 24 (5.3) 5 (6.3) 3 (7.5) 8 (6.7)
 Belgium 6 (2.0) 6 (3.9) 12 (2.6) 3 (3.8) 3 (7.5) 6 (5.0)
 Denmark 5 (1.7) 2 (1.3) 7 (1.5) 3 (3.8) 1 (2.5) 4 (3.4)
 Netherlands 9 (3.0) 3 (2.0) 12 (2.6) 2 (2.5) 1 (2.5) 3 (2.5)
 Sweden 5 (1.7) 2 (1.3) 7 (1.5) 3 (3.8) 2 (5.0) 5 (4.2)
Type of institution, n (%)
 General or regional hospital 91 (30.2) 42 (27.6) 133 (29.4) 20 (25.3) 12 (30.0) 32 (26.9)
 Oncology clinic/institute 30 (10.0) 9 (5.9) 39 (8.6) 7 (8.9) 5 (12.5) 12 (10.1)
 Private clinic/hospital 50 (16.6) 25 (16.4) 75 (16.6) 33 (41.8) 11 (27.5) 44 (37.0)
 University or teaching/training hospital 125 (41.5) 70 (46.1) 195 (43.0) 13 (16.5) 7 (17.5) 20 (16.8)
 Other 5 (1.7) 6 (3.9) 11 (2.4) 6 (7.6) 5 (12.5) 11 (9.2)
Size of institution, no. of inpatient bedsa 493.6 (465.6) 623.9 (434.5) 538.2 (475.6) 316.9 (525.4) 640.2 (570.7) 422.6 (559.0)
 Mean (SD) 400.0 500.0 500.0 50.0 455.0 250.0
 Median (Q1–Q3) (100.0–772.5) (310.0–895.5) (150.0–800.0) (17.0–400.0) (250.0–750.0) (23.0–625.0)
Size of oncology dept., no. of inpatient bedsa      39.2 (51.4)  
 Mean (SD) NR 38.6 (58.5) NR 30.0
 Median (Q1–Q3) NR 24.5 (14.0–45.0) NR (15.0–40.0)
No. of years’ experience as a practising oncologist specialising in mCRC
 Mean (SD) 12.5 (7.1) 13.1 (6.7) 12.7 (7.0) 15.7 (8.5) 13.9 (5.9) 15.1 (7.7)
 Median (Q1–Q3) 11.0 (7.0–16.0) 12.0 (8.0–18.0) 12.0 (7.0–17.0) 15.0 (10.0–20.0) 14.0 (10.0–17.5) 15.0 (10.0–20.0)
No. of patients with mCRC treated by the oncologist in the previous 3 months
 Mean (SD) 59.0 (57.7) 53.1 (44.6) 57.1 (53.7) 58.0 (69.0) 37.5 (54.9) 51.1 (65.1)
 Median (Q1–Q3) 40.0 (25.0–70.0) 40.0 (30.0–60.0) 40.0 (25.0–65.0) 36.0 (20.0–70.0) 28.0 (20.0–40.0) 30.0 (20.0–50.0)
No. of patients with mCRC treated with panitumumab in the last 6 months
 Mean (SD) NR NR NR 9.2 (9.1) 6.7 (5.6) 8.4 (8.2)
 Median (Q1–Q3) NR NR NR 6.0 (5.0–10.0) 5.0 (3.0–9.0) 6.0 (5.0–10.0)
  1. mCRC metastatic colorectal cancer, NR not recorded, Q quartile, SD standard deviation
  2. aRounds 1 and 2 of the study participants were asked only about the number of inpatient beds in their facility, which could have led to confusion regarding whether they should give the total number of beds in the hospital or in their oncology department. The survey was amended in Round 3 to prevent this confusion by specifically asking about both